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Increasing  threats  from  anthelmintic  resistant  nematode  populations  warrant  and  motivate
a reappraisal  of chemotherapeutic  strategies  for  nematode  control  in  ruminant  livestock
and horses.  The  objective  of  this  paper  is  to present  a  guideline  for the evaluation  of prod-
ucts containing  two  or more  constituent  anthelmintic  actives  in  a  single  dosage  form  for
the treatment  of  nematode  infections  in these  animals.  At present,  regulatory  policies  on
the approval  of such  products  vary  across  jurisdictions,  and  this  World  Association  for theorses
orm control
nthelmintic resistance
uidelines
Advancement  of Veterinary  Parasitology  (W.A.A.V.P.)  guideline  should  enable  the  harmo-
nization of  the requirements.  This  guideline  makes  clear  recommendations  on  the  minimal
standards  needed,  but stresses  that  registration  dossiers  for combination  anthelmintic
products  submitted  for approval  must  conform  to the  standards  and  practices  already
ting  guestablished  in exis
. Introduction
Economic pressure to obtain optimal performance
n ruminant livestock production has guided the use
f anthelmintics for many decades. Although there are
 number of different approaches to the control of
elminth parasites in ruminant livestock and horses, cur-
ent practice typically relies on the use of highly efﬁcacious
road-spectrum anthelmintics. Though unsustainable with
egard to selection for anthelmintic resistance (AR),
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routine treatment of the entire herd or ﬂock rather than
selective treatment of individuals (Corwin, 1997; Charlier
et al., 2009) has become commonplace, encouraged by data
showing that chemotherapeutic control of even subclinical
helminth parasitism can generate a return on investment
through gains in production (i.e., meat, milk, wool and
reproduction). This strategy, based on cost-beneﬁt analysis
in ruminants, has become so ingrained that it can be quite
difﬁcult to persuade producers to adopt practices that may
lead to reduced short-term income to protect the long-term
utility of an anthelmintic product.
When ﬁrst introduced, the broad-spectrum
anthelmintics, including benzimidazoles (BZ), nicotinic
acetylcholine receptor (nAChR) agonists (e.g., levamisole,
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LEV) and the macrocyclic lactones (ML), were highly
efﬁcacious. However, intensive use has selected drug-
resistant parasite populations globally in many animal
species within a decade of the introduction of every
anthelmintic class, and AR is now a major global problem
in small ruminants (Kaplan, 2004; Jabbar et al., 2006;
Waghorn et al., 2006; Kaplan and Vidyashankar, 2012)
and horses (Molento et al., 2012; Reinemeyer, 2012), and
is emerging in cattle (El-Abdellati et al., 2010; Sutherland
and Leathwick, 2011; Kaplan and Vidyashankar, 2012). For
the purposes of this guideline, AR may  be simply deﬁned
as a heritable change in susceptibility to an anthelmintic
in a population of parasitic nematodes such that a dose
which normally provides ≥95% clearance of adult worms
provides ≤80% clearance. Anthelmintic resistance is
arguably the greatest threat to the sustainable control
of helminthoses in the short- to medium-term and the
problem is compounded by the fact that many of these
parasite populations are resistant to more than one class
of anthelmintic (van Wyk  et al., 1997; Love et al., 2003;
Anziani et al., 2004; Wrigley et al., 2006; Sargison et al.,
2007; Sutherland et al., 2008; Gasbarre et al., 2009a,b;
Cezar et al., 2010; Baker et al., 2012; Molento et al., 2012;
Reinemeyer, 2012). Despite the scarcity of well-structured
surveys, it is generally accepted that the prevalence of AR
is increasing globally in the ruminant livestock industries
and in horses.
2. Combining anthelmintics: current situation
Drug combinations are commonly used for chemother-
apeutic indications in human medicine, including cancer
as well as viral, bacterial and protozoan parasitic infec-
tions (White, 1999; Miles et al., 2002; Anonymous, 2004;
Harrigan et al., 2005; Lane, 2006; Airley, 2009; World
Health Organization, 2009; Bang, 2010; Hastings, 2011).
The principle that combinations of chemotherapeutic
agents beneﬁt patients by maintaining drug efﬁcacy in the
presence of resistance has been repeatedly demonstrated
in this context for diverse pathogens and builds on knowl-
edge gained from insecticide, pesticide and herbicide use
(Wood and Mani, 1981; Curtis, 1985; Mani, 1985; Comins,
1986; Diggle et al., 2003). Currently, combinations of two
or more anthelmintics are primarily being used to manage
AR in ruminants (i.e., by delaying the emergence and spread
of resistance, and/or controlling parasite populations with
existing resistance), and to enlarge/expand the spectrum
of efﬁcacy.
The increasing problem of AR resulted in the develop-
ment, approval and widespread adoption of combinations
of two or more anthelmintic constituent actives in Australia
and New Zealand, where serious problems of AR in nema-
todes of small ruminants (both countries) and cattle
(primarily New Zealand) exist (Besier, 2003; Waghorn
et al., 2006; Sutherland and Leathwick, 2011). The global
spread of AR in sheep, goats and horses, coupled with
the emerging problem of AR in cattle, mandates the
development of new products and the implementation
of more sustainable application strategies to ensure ade-
quate parasite control in the future. Such strategies may
include the use of anthelmintic combinations to forestallology 190 (2012) 306– 316 307
productivity losses due to AR, along with the discovery and
development of novel anthelmintics. New drugs may well
exhibit a reduced spectrum compared to currently avail-
able drugs, but could provide effective parasite control in
regimens compatible with current (localized) management
practices if developed as combination products. This sit-
uation supports the contention that current anthelmintic
combination guidelines are inadequate and a consensus
is urgently needed to motivate and facilitate new product
development and regulatory approval.
Anthelmintic combination products incorporating two
or more constituent actives are also used to expand the
spectrum of efﬁcacy against nematode parasites. For exam-
ple, a new anthelmintic, derquantel (spiroindole class), has
recently been approved for use in some countries as a com-
bination anthelmintic product with abamectin (ML class).
By adding abamectin to derquantel, the spectrum of para-
site species against which this combination exhibits ≥95%
efﬁcacy is signiﬁcantly increased (Little et al., 2010, 2011).
There is precedence for licensing anthelmintic com-
bination products incorporating two or more constituent
actives to expand efﬁcacy against helminth parasites to
include organisms in more than one phylum (i.e., nema-
todes plus trematodes or cestodes). These combination
products are often developed based more on a combi-
nation of commercial interest and convenience for the
end-user than on rigorous considerations of differences
in the epidemiology of the disparate helminth targets
of the constituent actives. Combinations of a broad-
spectrum anthelmintic with a ﬂukicide (e.g., clorsulon or
triclabendazole) or cestocide (e.g., praziquantel) are avail-
able world-wide, for instance, but the appropriate timing
of ﬂuke treatment may  be an inappropriate time for nema-
tode treatment. While it is legitimate to be concerned
that anthelmintic combination products may  promote
indiscriminate or over-use of the product, the commer-
cial reality is that veterinary pharmaceutical companies
develop these products in response to producer demands
and seek regulatory approval on this basis. Moreover, they
mitigate the risk that end-users will dose animals with
self-prepared ‘cocktail’ mixtures that could contain incom-
patible components, including excipients, or that may  be
dosed at incorrect rates. This kind of self-compounded
combination of two or more narrow- or broad-spectrum
anthelmintics, even though legal in some countries under
veterinary supervision, is much less desirable than a com-
bination anthelmintic product that has gone through the
regulatory approval process, which will ensure that all
the components of the product, including excipients and
constituent actives, meet requirements for stability, safety
(target animal, user, consumer and environment) and efﬁ-
cacy.
Current problems for the approval of anthelmintic com-
bination products include the lack of universally accepted
guidelines for their development; various regulatory agen-
cies employ different approaches and policies for granting
approval of combination anthelmintic products for use in
ruminant livestock and horses. This situation may result
in poor management practices caused by the present
reluctance to accept anthelmintic combinations in some
jurisdictions (e.g., the European Union and the United
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tates of America). Since the control of resistant nema-
odes may  be similarly accomplished by separate dosing
ith multiple constituent actives in individual products,
 practice not prevented under existing regulations, it is
nlikely that a combination anthelmintic product would
ncentivize irresponsible use to a greater extent than what
lready exists with single-active products.
As noted, guidelines governing the approval of combi-
ations of anthelmintic constituent actives in ﬁxed-dose,
ingle dosage form products vary among countries. The
riving force for approval in countries in which these prod-
cts are registered has been the provision of medicines
apable of controlling multiple species of drug-resistant
ematodes (including populations resistant to one or more
lasses of anthelmintic), primarily of sheep and more
ecently cattle, and also to retard the development and
pread of AR as a longer-term goal. Control of existing
opulations of resistant parasites is much easier to demon-
trate and serves as the basis for approval in countries
n which combination products are allowed. Data are
merging to support the use of combination anthelmintic
roducts to slow the development and spread of AR, but
t would be challenging to incorporate data for this indica-
ion per se to support regulatory approval. Instead, label
equirements for these products include demonstration
f high efﬁcacy (e.g., in Australia >95%, Anonymous, not
ated) against a panel of resistant parasite species relevant
or the country. This is feasible for sheep parasites, but may
e difﬁcult to attain for resistant parasites of cattle, which
re less readily available as experimental isolates; the same
ituation pertains to equine parasites.
. Objectives of the anthelmintic combination
uideline
This new guideline relating to combination
nthelmintic products containing two or more con-
tituent actives is developed in the context of those used
y countries that already approve their use along with
he W.A.A.V.P. and VICH guidelines for general efﬁcacy
f anthelmintics (Anonymous, 1999a,b, 2000a,c, 2001;
ercruysse et al., 2001, 2002).
The goal is to provide a harmonized guideline for
se by veterinary pharmaceutical companies developing
ossiers for approval of ﬁxed-dose anthelmintic combina-
ion products by veterinary medicines regulators. Thus, the
ain goal of this guideline is to provide a scientiﬁc basis
o recommend globally applicable principles governing
he approval of ﬁxed-dose combinations of anthelmintic
onstituent actives. These include combination products
esigned to (1) cover the desired breadth of spectrum; (2)
inimize (delay) the development and spread of resistance
o new and existing anthelmintic classes;  or (3) overcome
xisting species-speciﬁc resistance proﬁles.  Speciﬁcally, it is
mportant to consider the scientiﬁc basis for the adoption or
rohibition of combination anthelmintics for the ruminant
nd equine markets, and to promote regulatory policies
hat enable adequate parasite control while maintaining
he highest standards of safety.
The guideline proposes the efﬁcacy data package
equired to justify the approval of anthelminticology 190 (2012) 306– 316
combination products containing two  or more constituent
actives from different pharmacological anthelmintic
classes in ﬁxed-dose, single dosage formulations for use in
ruminant livestock (sheep, goats and cattle) and horses.
These anthelmintic combination products could contain
constituent actives already approved for use in these
hosts or new constituent actives not previously approved
for sale. The combined constituent actives do not need
to exhibit completely overlapping spectra of parasites.
Approval should depend on demonstration of the normal
standards of product stability, safety, residues and efﬁcacy,
particularly against relevant resistant isolates and species
of targeted parasites.
Although combinations of drugs that control trema-
todes rather than nematodes have not been pursued as
avidly as combination products for nematodes, their reg-
ulatory approval could be justiﬁed on similar grounds.
Certain trematocides (ﬂukicides) selectively target differ-
ent stages of the parasite life cycle, and in theory, broader
control could be achieved by the use in combination of
constituent actives with efﬁcacy against immature and
mature stages of Fasciola hepatica, for instance. While con-
siderations similar to those proposed here for regulatory
approval of nematocidal combination products could be
applied to trematocidal combination products, speciﬁc dis-
cussion of these latter products will not be provided here.
This guideline does not consist of rigid stipulations, but
instead makes recommendations on the minimum studies
required (Wood et al., 1995; Vercruysse et al., 2001). Guide-
lines cannot address all possibilities and each case should
be considered on its merits; if alternative approaches are
deemed more ﬁtting, a reasoned argument should be dis-
cussed with regulatory agencies in the target jurisdiction.
Before describing the anthelmintic combination guideline,
rationales for the use of anthelmintic combination products
and concerns about ﬁxed-dose anthelmintic combination
products will be discussed.
4. Rationales for the use of anthelmintic
combination products
To deny on principle the use of combination products
for nematode infections requires some evidence that such
infections are fundamentally different from infections with
other kinds of pathogens (or from cancer). One excep-
tion pertains to the therapeutic coverage required. For
viral, bacterial and fungal infections, as well as cancer,
the target is 100% elimination of the pathogen (includ-
ing tumor cells) in every treated patient. These infections
are addressed as individual cases, unlike the population
treatment paradigms typically employed in anthelmintic
treatment strategies for ruminant livestock (and some-
times horses). Indeed, a key principle for slowing the
emergence of AR in parasitic nematodes of ruminant live-
stock or horses is to obtain the highest possible removal
of the parasites in signiﬁcantly infected animals while
ensuring that surviving parasites are diluted into a pool
of susceptible, untreated parasites in the local environ-
ment as a refugial population (Dobson et al., 2001, 2011b;
Bartram et al., 2012). This principle applies to single-
constituent active and combination products containing
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two or more distinct constituent actives (e.g., anthelmintics
from different chemical classes with distinct mechanisms
of resistance, or at least demonstrably different mecha-
nisms of action). It should be noted that this difference
does not contravene the potential therapeutic utility of
anthelmintic combination products for providing efﬁcacy
in the presence of AR and in delaying the onset and spread
of AR if used according to best practices (see Section 5.3).
4.1. Managing existing resistance
As noted, combinations of two or more anthelmintic
constituent actives have been approved and widely
adopted in Australia and New Zealand for use in ruminants.
The ﬁrst formulated combination products contained a
BZ and LEV as constituent actives and were introduced
into these countries in the early 1980s to control resis-
tant nematodes in sheep (Anderson et al., 1988; McKenna,
1990). A great deal of experience and knowledge pertain-
ing to the use of such products has subsequently been
gained. The wide use of anthelmintic combinations, often
necessitated by the very high frequency of resistance to
one or more available constituent actives when used alone,
has revealed no issues of special concern with the rou-
tine use of such products. It was to be expected that some
multiply-resistant nematode populations (e.g., Love et al.,
2003; Wrigley et al., 2006; Sutherland et al., 2008; Baker
et al., 2012) would ultimately be found in countries where
combinations were used, given the long history of use of
their components as single-constituent active anthelmintic
products, generating high ‘pre-existing’ resistance (R)-
allele frequencies in exposed parasite populations.
4.2. Delaying anthelmintic resistance
The role that anthelmintic combination products could
play in delaying the emergence of drug-resistant para-
sites was identiﬁed after commercial products of this
type were ﬁrst introduced to control resistant parasites
in sheep (Anderson et al., 1988). Mathematical simulation
studies demonstrated that the full beneﬁt of combina-
tion anthelmintic product therapy would be realized when
initial R-allele frequencies were low, and that the likeli-
hood of resistance occurring to a combination anthelmintic
product would increase with increasing R-allele frequency
to its individual constituent actives (Smith, 1990; Barnes
et al., 1995; Leathwick, 2012; Bartram et al., 2012). This
concept was later supported by an empirical study in
New Zealand (Leathwick et al., 2012). Fixed-dose com-
mercial anthelmintic combination products contain as
many as four anthelmintic constituent actives with differ-
ent mechanisms of action. Experience with such products
for the control of multiple-resistant isolates of several
nematode species has not uncovered undue toxicity or
safety concerns in the veterinary setting. While resistance
to a 4-way anthelmintic combination product (BZ, LEV,
abamectin, closantel) has been reported in Haemonchus
contortus (Baker et al., 2012), this observation serves only
to conﬁrm the beneﬁt of commencing use of combination
anthelmintic products when R-allele frequencies are low.ology 190 (2012) 306– 316 309
Theoretical considerations of the value of combina-
tion anthelmintic products have recently been discussed
(Leathwick et al., 2009; Bartram et al., 2012), and
the beneﬁts of such products were further demon-
strated in a simulation study using an Australian sheep
model with multiple parasite species. A key outcome
from this modeling was that a (theoretical) 4-way
combination of BZ–LEV–abamectin–monepantel (amino-
acetonitrile derivative class) was  the best option for
delaying the development of AR while achieving effective
nematode control despite the presence of resistance to the
ﬁrst three drugs (Dobson et al., 2011a,b).
Importantly, experimental and modeling data suggest
that the development of resistance to a new anthelmintic
will not be accelerated (and in most circumstances it will be
delayed) by its inclusion in a combination product (Dobson
et al., 2011a,b; Leathwick, 2012; Leathwick et al., 2012).
Indeed, this is a driving force for combination chemother-
apy of HIV, tuberculosis and malaria in humans (see above)
and may  be considered one of the key advantages of
anthelmintic combinations in geographic locations where
AR in cattle parasites is not already intensely distributed
(i.e., Europe, North America).
4.3. Speciﬁc targeting of dose-limiting species
The dose-limiting parasite species will generally be
identiﬁed during dose determination studies that iden-
tify the dose providing ≥90% efﬁcacy. Lower doses will
show efﬁcacy <90% for the dose-limiting species even
though they will adequately treat other parasites (i.e., efﬁ-
cacy ≥ 90%) (Vercruysse et al., 2001).
Dose-limiting species can be vulnerable to selection for
AR and at least on some occasions have been the ﬁrst to
reveal resistance, as is clearly evidenced with the MLs  and
cattle parasites. Current AR in cattle parasites is primarily
due to isolates of Cooperia spp. (Sutherland and Leathwick,
2011), which are the dose-limiting parasites for this drug
class (Vercruysse and Rew, 2002). Incorporating a second
anthelmintic constituent active with a ML  in a ﬁxed-dose
anthelmintic combination product could address concerns
around control of these parasites and signiﬁcantly delay
the spread and further selection of resistant Cooperia spp.
populations.
4.4. Maximizing breadth of spectrum
Two novel drugs with complementary nematode spec-
tra that are separately inadequate for livestock parasite
control could be combined in a ﬁxed-dose product to
provide therapeutically useful activity. An example in
companion animals is the combination of febantel with
pyrantel pamoate or oxantel (plus praziquantel), which
provides high efﬁcacy against the important gastrointesti-
nal nematode species in a single dose, whereas the single
agents require multiple doses for similar results when used
alone. There is no apparent disadvantage to this kind of
combination compared to a novel single agent product
with an equivalent overall spectrum of action, as long as
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afety and residue concerns (if used in food/ﬁber produc-
ion species) are adequately addressed.
. Concerns about ﬁxed-dose anthelmintic
ombination products
A primary principle of infectious disease chemotherapy
s to identify the pathogen in order to choose the most
ppropriate agent and treatment regime. In practice, this
rinciple is often ignored, given the costs associated with
iagnostic tests and procedures, and the delay in treatment
ncountered as the diagnosis is awaited. The availability
f truly broad-spectrum antibiotics and anthelmintics has
adically changed the expectations of patients, physicians,
eterinarians and livestock producers, essentially bypass-
ng the requirement for conﬁrmation of the pre-treatment
iagnosis.
Ideally, the species of parasitic nematodes present in a
ock or herd would be identiﬁed, along with susceptibil-
ty testing to determine which class(es) of anthelmintic(s)
hould be administered. However, this strategy is rarely
dopted by commercial operations, as it runs counter to the
erception that schemes based on enhanced diagnostics
or case management rather than herd or ﬂock treatment
dd labor costs and reduce convenience. Importantly, ani-
al  welfare considerations demand prompt treatment of
ny animal that is ill due to parasitism. Since the drug-
esistance status of parasites on farms is rarely determined
rior to choosing a treatment (Lawrence et al., 2007;
obson et al., 2011a; Morgan et al., 2012), an approach of
sing single-constituent active products for strategic dos-
ng to account for the species and AR status present at
he time is not likely to be practical or sustainable even
n smaller operations. This will be exacerbated as popu-
ations of multiply-resistant parasite populations spread,
equiring multiple treatments with different products in
eparate dosage forms to maintain control. In such sit-
ations, ﬁxed-dose anthelmintic combination products,
ather than administration of multiple doses of a number
f single-constituent active products, would reduce both
nimal stress and labor costs.
Three primary areas of concern (discussed in the fol-
owing sections) are apparent with ﬁxed-dose commercial
nthelmintic combination products, viz. drug–drug interac-
ions (safety and efﬁcacy implications of pharmacokinetics
nd pharmacodynamics), common mechanisms of resistance
nd best-practice management to ensure appropriate use for
ustainability of parasite control with the products.
.1. Drug–drug interactions
Safety concerns about ﬁxed-dose anthelmintic combi-
ation products are centered on the potential pharma-
okinetic and/or pharmacodynamic interactions that may
ccur between the constituent actives or the excipients
sed (Alvarez et al., 2008; Entrocasso et al., 2008; Suarez
t al., 2009; Lanusse, 2010), and the subsequent complica-
ions these interactions could cause for efﬁcacy, residues,
arget animal safety and environmental safety. However,
hile approval of a product containing different nematoci-
al constituent actives in a single dosage is not permittedology 190 (2012) 306– 316
by some regulatory agencies, no regulations are appar-
ent that prevent the concurrent administration of two or
more different registered anthelmintic constituent actives
to ruminants or horses at the owner’s discretion, providing
the products are administered in separate dosage forms.
Products containing ﬁxed-dose combinations of multiple
anthelmintic constituent actives have been approved and
are in wide use in some countries, but the authors are not
aware of reports of pharmacokinetic, toxicokinetic or phar-
macodynamic interactions associated with these products
in ruminant livestock. Nonetheless, the potential for such
interactions of individual constituent actives in any com-
bination anthelmintic product should be addressed in each
dossier for submission (for an example, see Cromie et al.,
2006) (see Section 6).
Combination chemotherapy products often are based
on using drugs with similar pharmacokinetic proﬁles on the
grounds that matching elimination curves will protect each
of the components from the selection of resistant pathogen
populations by maintaining consistent simultaneous expo-
sure. However, concerns about matching half-lives of
elimination to minimize exposure to suboptimal concen-
trations of single constituent actives or their bioactive
metabolites at the tail of the elimination curve may  be
more relevant for synergistic combinations. While syner-
gistic combinations have special value in chemotherapy,
and provide an adequate justiﬁcation for a combination
product, additive effects, at the least, are to be expected
and also justify a combination anthelmintic product (in
contrast, an antagonistic interaction in which the efﬁcacy
of the combination of constituent actives is lower than
would be predicted by their efﬁcacies when used alone
may  preclude regulatory approval; Fuhr, 2007). It should
not be a requirement for additive combinations that the
entirety of the pharmacokinetic proﬁles of the constituent
actives are highly similar; however, adequate overlap of
the time-to-kill curve for each agent must be observed to
ensure that they are present simultaneously in sufﬁcient
concentrations for sufﬁcient duration to attain co-incident
lethal exposures. This will subject the parasites to inde-
pendent chemotherapeutic pressures that will eliminate
or reduce the survival of individual worms with R-alleles
to only one of the constituent actives in the combination
product. It will not protect the longer-duration component
from selecting for resistance during a period of subopti-
mal  concentrations at the tail of the elimination curve, but
this situation is not different than what would be experi-
enced if that constituent active is used alone in a product.
Deviation from this pattern can be tolerated if supported
by evidence that differences in the pharmacokinetic pro-
ﬁles of the constituent actives still subject the parasites
to the additive effects needed to avoid independent and
sequential selection for resistance.
5.2. Common mechanisms of resistance
An anthelmintic combination product is only appro-
priate if its constituent actives do not share the same
mechanism of resistance (noting this is different from
mechanism of action). Most experience suggests that
anthelmintics from the various pharmacological classes do
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not exhibit common mechanisms of resistance, although
these mechanisms remain poorly understood; and there is
no experimental or conﬁrmed ﬁeld evidence that develop-
ing resistance to one class predisposes to the development
of resistance in another class. Mottier and Prichard (2008)
have questioned the use of anthelmintic combination
products containing a BZ and a ML  on the basis that
repeated exposure of H. contortus to ML  anthelmintics pro-
moted allelic changes in the -tubulin isotope 1 gene, the
key locus involved in the mechanism of BZ resistance.
This observation may  have implications for the use of
anthelmintic combination products containing constituent
actives in these classes, but it is not clear that it represents
true cross-resistance (Leathwick et al., 2009). Leathwick
et al. (2009) further point out that, while Mottier and
Prichard (2008) suggest that MLs  may  act as modiﬁers
of BZ resistance, no pharmacological evidence has been
advanced to show that nematodes resistant to MLs  will
also be resistant to BZs. Additionally, it is not clear that a
limited degree of cross-resistance, should it exist, would
be sufﬁcient to nullify the beneﬁts of administering the
anthelmintics in combination (Leathwick et al., 2009).
That single-constituent active products from these
classes are already used in areas of existing drug resistance
suggests that products containing them in combination
pose no greater risk of selection for multiple-drug resis-
tance than would be encountered if they were used in
rotation or administered concurrently in separate dosage
forms.
Similarly, adding a novel constituent active to an
anthelmintic combination product that includes existing
constituent actives, as opposed to using it alone or in rota-
tion in areas where resistance already exists, should not
predispose it to a more rapid selection for evolution of
parasite resistance as demonstrated in recent modeling
and empirical studies (Dobson et al., 2011a,b; Leathwick,
2012; Leathwick et al., 2012). Proof of efﬁcacy of com-
binations against existing resistant parasite isolates in
dose-determination experiments will alleviate this con-
cern to some extent, although only ﬁeld use will reliably
reveal if selection of a resistance mechanism that crosses
anthelmintic classes can occur in nematode populations
following the use of a new drug.
5.3. Best-practice management of combination
anthelmintics
As noted above, few farmers test for AR (Lawrence et al.,
2007; Dobson et al., 2011a; Morgan et al., 2012). Under
these circumstances, a concern is that ﬁxed-dose combina-
tion anthelmintic products could mask the development of
resistance. This may  be considered a technology transfer or
compliance problem that does not change the conclusions
from modeling studies that resistance will be substantially
delayed by administering anthelmintic combination prod-
ucts in comparison to rotation or sequential use strategies
of single-constituent active products (Smith, 1990; Barnes
et al., 1995; Leathwick, 2012). Fixed-dose combination
anthelmintic products appear to slow the development of
resistance because they afford the highest possible kill of
nematodes (Bartram et al., 2012). Parasites that survive oneology 190 (2012) 306– 316 311
constituent active in the combination are killed by the other
constituent active(s); individual parasites that possess two
distinct R-alleles, each of which is present in the population
at very low frequencies, will initially be very rare.
However, the use of anthelmintic combination products
does not eliminate the signiﬁcant risk for resistance posed
by dosing strategies that allow livestock to graze clean
(low contamination) pastures after treatment. This practice
readily selects for resistant populations as the parasites
that survive the treatment become the major source of sub-
sequent contamination on these pastures (LeJambre, 1978;
Cawthorne and Whitehead, 1983; Michel, 1985; Taylor and
Hunt, 1988, 1989). This concern is obviously more acute if
resistance to one of the constituent actives in the combina-
tion product is already present and unsuitable treatment
regimes are implemented.
The beneﬁts of maintaining a population of nematodes
in refugia, as a means of slowing the development of drug
resistance, were ﬁrst advanced by Martin et al. (1981)
and should not be underestimated; van Wyk  (2001) and
Dobson et al. (2001) proposed that refugia could be the
most important factor in determining the rate at which
AR develops. Full consideration should be given to refugia
when designing and implementing nematode control pro-
grams. With heightened scientiﬁc interest in maintaining
adequate refugia as a means of slowing the development of
AR, considerable improvements have been made in recent
years to our understanding of the concept (Kenyon et al.,
2009; Leathwick et al., 2009; Bartram et al., 2012).
For ruminants, the number of animals that should be
left untreated to create an adequate refuge of parasites will
vary between breed and age (i.e., level of immunity), farm
management practices, anthelmintic treatments (which
includes consideration of efﬁcacy and AR status), nema-
tode species (including the potential for hypobiotic stages),
and geographic region (with an overlying inﬂuence of cli-
mate on the development and survival of the free-living
parasite stages on pasture). Examples of generally accepted
strategies to establish adequate refugia include: grazing
untreated adults with younger animals that are treated;
ensuring that the interval between treatments allows
some contamination of pasture with unselected parasites;
treating animals several days after moving to relatively
worm-free pasture to contaminate the area with unse-
lected nematodes; or leaving a proportion of animals with
a group untreated. This mix  of factors creates an extremely
complex environment in which simulation models can be
of more beneﬁt than ﬁeld experiments (Hosking, 2010;
Dobson et al., 2011b). Thus, the propensity for selection
of resistant nematode populations through an inadequate
population of parasites in refugia is a matter of concern for
all anthelmintic products and hence is another technology
transfer problem for any new product, whether composed
of single or multiple constituent actives. It should be noted
that little work has been done on the role of refugia in the
development of AR in horses, but it would be conservative
to assume that the importance is similar to the situation in
ruminants.
In any case, animal health advisors must capture
every opportunity to strongly reinforce best-practice man-
agement to their clients. The principles of continuing
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ducation are the same whether producers use single-
onstituent active or combination anthelmintic products.
his includes testing for AR to identify suitable constituent
ctives, estimating (however inadequately) nematode bur-
ens and species by fecal egg counts (FEC) and preferably
arval culture (or PCR) to determine appropriate treatment
egimens, and the management of pasture exposures to
educe the overall parasite challenge in balance with the
aintenance of drug-susceptible populations in refugia,
hich can help slow the development of AR in nematodes
Barger, 1999; Dobson et al., 2001, 2011b; van Wyk, 2001;
aker et al., 2012; Bartram et al., 2012).
. Efﬁcacy guideline for regulatory
pproval/registration of anthelmintic combination
roducts to control nematode infections of
uminant livestock and horses
The composition of product dossiers for regulatory eval-
ation will be based on existing requirements already
stablished for single-constituent active products, includ-
ng dose determination and conﬁrmation studies, ﬁeld and
ersistent efﬁcacy studies, and using accepted standards of
ffectiveness and deﬁnition of helminth control claims in
ultiple species according to W.A.A.V.P. guidelines (Jacobs
t al., 1994; Wood et al., 1995; Duncan et al., 2002;
azwinski et al., 2003; Hennessy et al., 2006) and VICH
Anonymous, 1999a,b, 2000a,c, 2001; Vercruysse et al.,
001, 2002).
Dossiers submitted for the approval of anthelmintic
ombination products to control nematode infections of
uminant livestock and equines should also include at
east the following information: (1) justiﬁcation for the
ombination, including evidence that the anthelmintic
onstituent actives do not share a mechanism of resistance,
o the extent that this is known, (2) dose determination
ata for the constituent actives in the combination (of par-
icular importance if one of the constituent actives has not
een previously approved and so data are unavailable for
eference), (3) target animal safety and pharmacokinetic
ata showing non-interference and acceptable safety, (4)
ose conﬁrmation including persistent efﬁcacy and efﬁcacy
gainst resistant isolates if claimed in the application, and
5) ﬁeld efﬁcacy.
.1. Justiﬁcation for the combination
Before a combination anthelmintic product can be
onsidered, a detailed justiﬁcation for the combination,
ncluding the anticipated beneﬁts, is necessary. Justiﬁca-
ion of combinations should be clearly based on at least
ne of the following considerations, with each constituent
ctive of the combination addressed:
Overcoming lack of efﬁcacy for existing resistant nema-
tode species and preservation of the useful clinical
activity of existing anthelmintics.
Delaying the selection and spread of resistance to new
anthelmintic constituent actives.
Speciﬁc targeting of dose-limiting parasite species.ology 190 (2012) 306– 316
• Proven anthelmintic synergism of the constituent
actives.
• Additional parasite species claims.
6.2. Dose determination data on the anthelmintic
constituent actives in the combination
If the anthelmintic constituent actives to be used in the
combination product are already registered in the same
formulation and same route of administration used for
the combination product, efﬁcacy data will be available
and new studies will not be required for dose determina-
tion if all constituent actives are used at approved doses
(and in the absence of untoward results from studies dis-
cussed in Section 6.3). However, proof of efﬁcacy of the
ﬁxed-dose combination for the intended indications will
be required from dose conﬁrmation and ﬁeld studies (Sec-
tions 6.5 and 6.6). If existing anthelmintics are combined in
a formulation in which at least one constituent active has
not been approved, dose determination studies should be
done; pharmacokinetic studies that demonstrate plasma-
level bioequivalence of the new and previously approved
formulation do not necessarily predict efﬁcacy in other
compartments, including the gastrointestinal tract.
For new anthelmintic constituent actives, dose determi-
nation efﬁcacy data must be provided according to existing
W.A.A.V.P. (Wood et al., 1995; Duncan et al., 2002) and VICH
(Anonymous, 1999a,b, 2000a,b,c; Vercruysse et al., 2001,
2002) guidelines. If claims of synergy are made, conclusive
evidence supporting lowered doses (if used) must be pro-
vided in accordance with the relevant guidelines. It should
be noted that combination products that contain syner-
gistic constituent actives would not require independent
testing of the individual anthelmintics, as the efﬁcacy of the
combination product would clearly be dependent on their
simultaneous presence. Synergistic combinations should
instead be evaluated according to existing regulations for
single constituent active products.
6.3. Target animal safety and pharmacokinetic data
showing non-interference and acceptable safety
Although previous efﬁcacy guidelines did not address
issues of target animal safety or pharmacokinetics, even
though these ﬁelds are required for product approval by
regulatory authorities, the unique situation pertaining to
anthelmintic combination products requires some consid-
eration.
While reports of drug–drug interactions and enhanced
toxicity in ruminant livestock or horses are not appar-
ent for anthelmintic combination products, data justifying
the combination in terms of possible interactions at the
pharmacokinetic and pharmacodynamic levels, and evi-
dence of acceptable safety will nonetheless need to be
provided. Safety studies should be conducted with the min-
imal number of animals required to demonstrate safety;
the availability of data from previous approval dossiers
that prove safety of the combination of anthelmintic
constituent actives in the same formulation, or another for-
mulation that provides pharmacokinetic bioequivalence,
could minimize the requirement for additional studies. In
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each case, approval of all dosage forms and routes of admin-
istration should be predicated on regulatory requirements
for such products established in the various jurisdictions in
which approval is sought. Consultation on these require-
ments should be sought before such studies commence.
6.4. Product bioequivalence
The principle of product bioequivalence for the indi-
vidual anthelmintic constituent actives in question cannot
simply be applied to the ﬁxed-dose combination product,
as it could comprise formulation changes to the approved
individual anthelmintic constituent actives. Pharmacoki-
netic data alone cannot be used to justify approval of an
anthelmintic combination product, because it is not possi-
ble to conclude on that basis that the constituent actives
will not show pharmacological antagonism against target
parasite species. As noted above, there may  be a poor corre-
lation between plasma pharmacokinetics and anthelmintic
efﬁcacy for gastrointestinal parasites. Thus, the dossier
must include data from dose conﬁrmation and ﬁeld studies
proving the efﬁcacy of the combination product, compared
to the individual constituent actives administered alone
(Section 6.5).
6.5. Dose conﬁrmation studies
The design and analysis of dose conﬁrmation studies for
the anthelmintic combination product should be based on
the rationale for approval of the combination anthelmintic
product as described in Section 4. It should be noted in this
context that the goal of delaying the onset of AR is unlikely
to be adequately addressed in animal studies. Thus, dose
conﬁrmation studies need to be conducted in a location(s)
and in such a manner that the chosen rationale(s) is sup-
ported by data and meets the requirements of the current
guidelines for anthelmintics. At least one dose conﬁrma-
tion study must be conducted with the ﬁnal formulation to
be commercialized and should include the dose-limiting
parasite(s) for each anthelmintic used in the combination.
The number, location, design and analysis of these
studies should be based on existing guidelines for single-
constituent active products (Section 6.2). To investigate
efﬁcacy against adult parasites, naturally infected ani-
mals are preferred and infections should include, where
possible, known drug-resistant isolates or populations
of nematodes; strains resistant to one or more of the
anthelmintic constituent actives in the combination should
be included if available. The efﬁcacy of each individual
constituent active in the combination should be veriﬁed
against the presumed resistant isolates to validate the
inclusion of data from these trials in the dossier (e.g.,
the resistant populations must be proven to be present).
Efﬁcacy against larval stages should be determined using
experimental infections of nematodes from drug-resistant
isolates (including, if available, isolates obtained within
the previous 10 years) to permit claims on the product
label. For such purposes, ‘resistance’ can attributed to a
population of a parasite species that exhibits substan-
tial reductions in efﬁcacy (e.g., to ≤80%) when treated
with a dose of the anthelmintic which is historically ≥95%ology 190 (2012) 306– 316 313
efﬁcacious against that species (based on adequate evi-
dence from worm counts and/or FEC reductions) (Coles
et al., 1992; Anonymous, 2003). These isolates should encom-
pass the extent of AR present in the country of interest
and should be agreed by the relevant regulatory agency
as part of the preliminary discussions over the content of
the dossier required for consideration for approval. Efﬁcacy
against nematode species that can exist as hypobiotic lar-
vae should be included in the studies if label claims for such
parasites are sought. Analyses of parasite data in support
of efﬁcacy claims should be based on estimates of adult
and larval stage worm counts as speciﬁed in the earlier
guidelines (Section 6.2).
6.6. Field efﬁcacy studies
Field efﬁcacy studies shall be conducted using reduc-
tion in FEC (with supporting larval culture or PCR data)
after treatment with the ﬁnal formulation of the combina-
tion product to be commercialized to conﬁrm efﬁcacy and
safety in the ﬁeld in accordance with the current guide-
lines for single constituent active products (Wood et al.,
1995; Anonymous, 1999a,b, 2000a,b,c; Vercruysse et al.,
2001, 2002). The number of ﬁeld studies to be conducted
and the number of animals in each study will depend on
(1) the animal species and age, (2) the geographic loca-
tion, (3) local/regional regulatory requirements, and (4)
the rationale for the combination product as noted in Sec-
tion 6.1.  The controls should include untreated animals and
preferably animals treated with registered anthelmintics
with known proﬁles, including those used in the combi-
nation product. ‘Local/regional’ implies within a country
and/or association with a climatic and/or management
area. To achieve the desired numbers, it is also accept-
able to conduct multi-center studies with sub-studies in
each locality/region. The request for additional (or fewer)
studies, and/or animals (animal welfare considerations)
from local regulatory authorities should be fully justiﬁed.
The combination product should always be tested in the
age range/class/production type of animal intended to be
treated as indicated on the proposed product label.
7. Conclusions
The goal of this guideline is to provide a scientiﬁc
basis upon which to recommend globally applicable prin-
ciples governing the approval of ﬁxed-dose, single dosage
form combinations of anthelmintic constituent actives
with similar spectra of activity. This guideline must be
used in conjunction with existing VICH and W.A.A.V.P.
guidelines. The authors have identiﬁed no scientiﬁc consid-
erations that should prevent approval of properly justiﬁed
anthelmintic combination products for use in ruminant
livestock and horses to control nematode parasites.Acknowledgments
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Glossary
Adequate infection: Natural or induced infection level deﬁned in the study
protocol that will allow the evaluation of the therapeutic effectiveness
of the drug or product when comparing parasitological parameters
(e.g., number of parasites) in medicated and control animals.
Anthelmintic combination product: A pre-formulated single dosage form of
two  or more constituent anthelmintic actives.
Anthelmintic resistance: The ability of parasites to survive doses of drugs
that would normally kill parasites of the same species and stage. It is
inherited and selected for because the survivors of drug treatments
pass genes for resistance on to their offspring. These genes are initially
rare in the population or arise as rare mutations, but as selection con-
tinues, the proportion of resistance genes in the population increases
as  does the proportion of resistant parasites.
Claim: A parasite species or genus (adult and/or larvae) listed on the
labeling with proven susceptibility (90% or better effectiveness) to
an anthelmintic product.
Controlled study: A study to determine the effectiveness of a drug or
product using two  groups of adequately infected experimental ani-
mals, viz. the treated and control groups. After a suitable period of
time after treatment the animals are necropsied, and the parasites
enumerated and identiﬁed. The percentage efﬁcacy of the drug or
product is calculated: 100 × [(geometric mean of parasites in control
group) − (geometric mean of parasites in treated group)] divided by
(geometric mean of parasites in control group). It should be noted
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that  the use of arithmetic rather than geometric means for this pur-
pose remains under investigation, and this method for calculation of
efﬁcacy may  change in the future.
ose conﬁrmation study: In vivo study to conﬁrm the effectiveness of a
selected drug dose and formulation; may  typically be conducted in
the ﬁeld in pens or paddocks.
ose determination study: In vivo study to determine the most appropriate
dose or range of effectiveness of a veterinary drug.
ose-limiting parasite: A parasite that will be identiﬁed during dose deter-
mination studies that will identify the dosage of drug at which it shows
90% effectiveness. Any lower concentration of the drug will show
effectiveness below 90% for the dose-limiting parasite even though
it  will adequately treat other parasites (90% or better effectiveness) in
the  host.
ffectiveness: The degree to which the manufacturers’ claims on the label-
ing  have been supported by adequate data, i.e., providing control of
at  least 90% on the basis of the calculation of geometric means using
pooled data from controlled studies.
ield efﬁcacy study: Larger scale study to determine effectiveness and
safety of a veterinary product under actual use conditions.
CP: Good Clinical Practice: a guideline (from VICH) describes the GCP pro-
cesses intended to promote the quality and validity of test data. GCP
covers the conditions under which studies are planned, performed,
monitored, recorded and reported.ology 190 (2012) 306– 316
Geographical location: A subdivision where the guidelines will be imple-
mented, including but not limited to Australia/New Zealand, the
European Union, Japan, the USA, or South America.
(Field) isolate: A collection of a sub-population of helminths for the con-
duct of drug and product effectiveness tests isolated from the ﬁeld
less than 10 years ago. The helminths are considered representative
of current parasitic infections in the ﬁeld and have been characterized
(source, date, location, previous anthelmintic exposure and mainte-
nance procedures).
Multiply drug resistant: The existence of simultaneous resistance to more
than one anthelmintic class in a population of a single species of par-
asitic nematode.
Region: An area within a geographical location deﬁned by cli-
matic conditions, target animal husbandry and parasite resistance
prevalence.
Synergism: The interaction of two components of a combination product
such that the efﬁcacy is of the components administered together is
signiﬁcantly higher than the sum of the efﬁcacies of the two when
administered alone.
VICH: International Cooperation on Harmonisation of Technical Require-
ments for Registration of Veterinary Medicinal Products.
W.A.A.V.P.: World Association for the Advancement of Veterinary Parasi-
tology.
